AtriCure Net Worth
AtriCure Net Worth Breakdown | ATRC |
AtriCure Net Worth Analysis
AtriCure's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including AtriCure's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of AtriCure's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform AtriCure's net worth analysis. One common approach is to calculate AtriCure's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares AtriCure's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing AtriCure's net worth. This approach calculates the present value of AtriCure's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of AtriCure's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate AtriCure's net worth. This involves comparing AtriCure's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into AtriCure's net worth relative to its peers.
Enterprise Value |
|
To determine if AtriCure is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding AtriCure's net worth research are outlined below:
| AtriCure appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 399.25 M. Net Loss for the year was (30.44 M) with profit before overhead, payroll, taxes, and interest of 245.94 M. | |
| Over 97.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from businesswire.com: Az ATRC VentureOne a kvantumkorszak adatbiztonsgnak rdekben elindtja a QuantumGate-et a CyberQ-nl |
AtriCure Quarterly Good Will |
|
AtriCure uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in AtriCure. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to AtriCure's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of February 2024 Upcoming Quarterly Report | View | |
| 7th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know AtriCure's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as AtriCure is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading AtriCure backward and forwards among themselves. AtriCure's institutional investor refers to the entity that pools money to purchase AtriCure's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 1.2 M | Ubs Asset Mgmt Americas Inc | 2024-09-30 | 1 M | Gw&k Investment Management, Llc | 2024-09-30 | 1 M | Fmr Inc | 2024-09-30 | 973.5 K | Millennium Management Llc | 2024-06-30 | 952.8 K | Fiera Capital Corporation | 2024-06-30 | 918.2 K | Neuberger Berman Group Llc | 2024-06-30 | 868.4 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 782.9 K | Wasatch Advisors Lp | 2024-09-30 | 769.3 K | Vanguard Group Inc | 2024-09-30 | 4.7 M | Blackrock Inc | 2024-06-30 | 4.6 M |
Follow AtriCure's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.76 B.Market Cap |
|
Project AtriCure's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.10) | (0.10) | |
| Return On Capital Employed | (0.05) | (0.05) | |
| Return On Assets | (0.05) | (0.05) | |
| Return On Equity | (0.07) | (0.07) |
When accessing AtriCure's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures AtriCure's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of AtriCure's profitability and make more informed investment decisions.
Please note, the presentation of AtriCure's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, AtriCure's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of AtriCure's management manipulating its earnings.
Evaluate AtriCure's management efficiency
AtriCure has return on total asset (ROA) of (0.0351) % which means that it has lost $0.0351 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0839) %, meaning that it created substantial loss on money invested by shareholders. AtriCure's management efficiency ratios could be used to measure how well AtriCure manages its routine affairs as well as how well it operates its assets and liabilities. As of November 29, 2024, Return On Tangible Assets is expected to decline to -0.1. In addition to that, Return On Capital Employed is expected to decline to -0.05. At present, AtriCure's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 365.1 M, whereas Other Assets are forecasted to decline to 0.95.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 10.07 | 10.57 | |
| Tangible Book Value Per Share | 3.61 | 3.80 | |
| Enterprise Value Over EBITDA | (202.61) | (192.48) | |
| Price Book Value Ratio | 3.55 | 3.76 | |
| Enterprise Value Multiple | (202.61) | (192.48) | |
| Price Fair Value | 3.55 | 3.76 | |
| Enterprise Value | 73.6 M | 54.9 M |
The strategic initiatives led by AtriCure's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Enterprise Value Revenue 3.821 | Revenue 447.6 M | Quarterly Revenue Growth 0.179 | Revenue Per Share 9.564 | Return On Equity (0.08) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AtriCure insiders, such as employees or executives, is commonly permitted as long as it does not rely on AtriCure's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AtriCure insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
AtriCure Corporate Filings
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
| 12th of November 2024 Other Reports | ViewVerify | |
10Q | 30th of October 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
8K | 29th of October 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
AtriCure Earnings per Share Projection vs Actual
AtriCure Corporate Management
| Deborah Yount | Chief Officer | Profile | |
| Valerie StorchWillhaus | Vice Communications | Profile | |
| Tonya SPHR | VP HR | Profile | |
| Vinayak Doraiswamy | Chief Officer | Profile | |
| Amalio MD | Ex Officer | Profile | |
| JD CCEP | Chief Officer | Profile |
Already Invested in AtriCure?
The danger of trading AtriCure is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AtriCure is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AtriCure. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AtriCure is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether AtriCure offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AtriCure's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Atricure Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Atricure Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AtriCure. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade AtriCure Stock refer to our How to Trade AtriCure Stock guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AtriCure. If investors know AtriCure will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AtriCure listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.83) | Revenue Per Share 9.564 | Quarterly Revenue Growth 0.179 | Return On Assets (0.04) | Return On Equity (0.08) |
The market value of AtriCure is measured differently than its book value, which is the value of AtriCure that is recorded on the company's balance sheet. Investors also form their own opinion of AtriCure's value that differs from its market value or its book value, called intrinsic value, which is AtriCure's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AtriCure's market value can be influenced by many factors that don't directly affect AtriCure's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AtriCure's value and its price as these two are different measures arrived at by different means. Investors typically determine if AtriCure is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AtriCure's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.